Abstract

BackgroundTo compare the efficacies of univariate and radiomics analyses of amide proton transfer weighted (APTW) imaging in predicting isocitrate dehydrogenase 1 (IDH1) mutation of grade II/III gliomas.MethodsFifty-nine grade II/III glioma patients with known IDH1 mutation status were prospectively included (IDH1 wild type, 16; IDH1 mutation, 43). A total of 1044 quantitative radiomics features were extracted from APTW images. The efficacies of univariate and radiomics analyses in predicting IDH1 mutation were compared. Feature values were compared between two groups with independent t-test and receiver operating characteristic (ROC) analysis was applied to evaluate the predicting efficacy of each feature. Cases were randomly assigned to either the training (n = 49) or test cohort (n = 10) for the radiomics analysis. Support vector machine with recursive feature elimination (SVM-RFE) was adopted to select the optimal feature subset. The adverse impact of the imbalance dataset in the training cohort was solved by synthetic minority oversampling technique (SMOTE). Subsequently, the performance of SVM model was assessed on both training and test cohort.ResultsAs for univariate analysis, 18 features were significantly different between IDH1 wild-type and mutant groups (P < 0.05). Among these parameters, High Gray Level Run Emphasis All Direction offset 8 SD achieved the biggest area under the curve (AUC) (0.769) with the accuracy of 0.799. As for radiomics analysis, SVM model was established using 19 features selected with SVM-RFE. The AUC and accuracy for IDH1 mutation on training set were 0.892 and 0.952, while on the testing set were 0.7 and 0.84, respectively.ConclusionRadiomics strategy based on APT image features is potentially useful for preoperative estimating IDH1 mutation status.

Highlights

  • World Health Organization (WHO) grade II/III gliomas include a heterogeneous group of infiltrative neoplasms with astrocytic and oligodendroglia morphology (Louis et al, 2016)

  • Radiomics strategy based on APT image features is potentially useful for preoperative estimating isocitrate dehydrogenase 1 (IDH1) mutation status

  • In the 2016 WHO classification of central nervous system (CNS) tumors, grade II/III astrocytomas are molecularly divided into IDH mutant, IDH wild-type, and not otherwise specified categories, emphasizing the diagnostic and prognostic value of IDH mutation status in glioma (Louis et al, 2016)

Read more

Summary

Introduction

World Health Organization (WHO) grade II/III gliomas include a heterogeneous group of infiltrative neoplasms with astrocytic and oligodendroglia morphology (Louis et al, 2016). Highly variable clinical behaviors are not adequately predicted based on the histologic phenotype (van den Bent, 2010; Reuss et al, 2015). Patients with IDH mutation were more sensitive to chemoradiation therapy and survived longer than IDH wild-type ones (Sanson et al, 2009; van den Bent et al, 2010). IDH mutation would help stratify grade II/III gliomas into subgroups with distinct prognostic characteristics, therapeutic response, and clinical management (Rohle et al, 2013; Olar et al, 2015; Reuss et al, 2015; Jiang T. et al, 2016). To compare the efficacies of univariate and radiomics analyses of amide proton transfer weighted (APTW) imaging in predicting isocitrate dehydrogenase 1 (IDH1) mutation of grade II/III gliomas

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call